Novartis aims for Q2 Bexsero filing; Boehringer wins NICE nod on first cancer drug; Merck nabs FDA approval for IV Noxafil;

@FiercePharma: Best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @FiercePharma

@TracyStaton: Tops at FiercePharma Wed.: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. More | Follow @TracyStaton

@EricPFierce: New twist on KV vs FDA over Makena. FDA cites compounder. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> After a Drexel University student died of a meningitis B infection, Novartis ($NVS) said it's aiming to file for FDA approval for its vaccine against the strain, Bexsero, during the second quarter. Report

> Germany-based Boehringer Ingelheim's first cancer drug, Giotrif (afatinib), won a draft recommendation from U.K. cost-effectiveness watchdogs as a treatment for non-small cell lung cancer. Report

> The FDA approved Merck's ($MRK) antifungal treatment Noxafil for intravenous use. Report

> Japan's Eisai plans to amp up production at a Vizag, India, plant to 2 billion tablets by 2016. Report

> Infectious disease prevalence in Latin America, plus a lack of available treatments, opens up opportunities for drugmakers in the region, a Frost & Sullivan study found. Report

> The European Federation of Pharmaceutical Industries and Associations (EFPIA) has mounted a social media campaign aimed at members of the European Parliament. Report

> Spain's Almirall plans to issue €325 million ($453 million) in senior notes. Report

Medical Device News

@FierceMedDev: Staar got key FDA panel backing for its new ocular lens. Chances for approval now pretty high. More | Follow @FierceMedDev

@MarkHFierce: Boston Scientific gained a CE mark for new MRI-safe pacer leads. News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: NeuroDerm preps for Parkinson's patch PhII trial. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Following the 5-second rule for food is like playing Russian roulette with your gut, says one molecular biologist. Article | Follow @EmilyWFierce

> Smith & Nephew clears a major U.S. regulatory hurdle for ArthroCare merger. Story

> Samsung's Galaxy S5 smartphone escapes med device label in S. Korea. More

Biotech News

@FierceBiotech: ICYMI over the weekend: Chimerix started the week as a punching bag, then pulls off a TKO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers inks a $350M deal to pair with FivePrime on immuno-oncology gold rush. Story | Follow @JohnCFierce

@DamianFierce: Amgen hits the mark in another of its 14 PhIII studies of the PCSK9-blocking evolocumab. Release | Follow @DamianFierce

@EmilyMFierce: NIH cuts, sequestration hampering cancer research. Story | Follow @EmilyMFierce

> Intercept scores a PhIII win for lead drug following Friday night frights. More

> Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII. Article

CRO News

> Charles River snaps up Galapagos' CRO biz for $179M. News

> Clinipace dives into Asia with Choice Pharma buyout. Story

> WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals. Article

> Post-merger BioClinica looks to corner the imaging market. Piece

> PPD lands a federal bioterror deal worth up to $100M. News

> Meet DPx, the result of a $2.6B CMO merger. Brief

Biotech IT News

> Illumina likely to start charging for BaseSpace storage and processing in 2014. Story

> IMS: Big Pharma must turn to tech to cut $36B from their operating costs. Article

> Public enthusiastic--but wary--about sharing personal health data. Survey

> The rise of the Silicon Valley biocomputing startup. Piece

> Drop in federal funding threatens 22 jobs at the Broad Institute. Story

> Genome data nonprofit aims to raise $25,000 through crowdfunding. Brief

And Finally... The incidence of colon cancer plunged 30% over the past decade in 50-and-older Americans as more people had colonoscopies. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.